Buyi Qinggong Powder veterinary grade API is a multicomponent botanical powder supplied as an active pharmaceutical starting material for conversion into tablets, injections, capsules, powders, granules, premixes, and solutions. The material is not a single-molecule isolate; it is defined by a specification-constrained matrix of plant-derived constituents. Because no universal pharmacopoeial model designation exists for this grade, a manufacturer-specific material code—typically a letter prefix followed by BQG-API and the internal batch number—is assigned in the site master batch record. The designation must be traceable to the raw material release certificate, supplier audit, and quarantine status.

Use of the powder as an active pharmaceutical ingredient for injections does not mean that the dry powder is injectable. It means the material can serve as the starting substance for a licensed manufacturing process in which extraction, purification, and depyrogenation steps produce an injectable solution. For tablets and capsules, the powder is wet granulated or dry granulated to improve flow and compressibility. For powders, granules, premixes, and solutions, the material is sieved, blended, or extracted according to the finished-dose master formula. The product is sold only as a veterinary-grade starting material and is not intended for direct administration to animals without downstream processing.

Physicochemical and microbiological specification bands are route-dependent

Release testing for the powder should cover at least the following identity and purity parameters: appearance and color, odor, microscopic powder characters, thin-layer chromatographic or high-performance liquid chromatographic marker profile, loss on drying, total ash, acid-insoluble ash, heavy metals, arsenic, total aerobic microbial count, total combined yeasts and moulds, and the absence of Escherichia coli and Salmonella species. The exact numerical limits are route- and dossier-specific. A tablet or capsule applicant may accept a wider moisture band than an injectable extraction applicant, because residual moisture is removed or controlled during granulation; an injectable manufacturer typically sets a narrower loss-on-drying specification to reduce hydrolytic degradation and microbial proliferation in the stored powder.

Particle-size distribution should be determined by laser diffraction in accordance with ISO 13320:2020 or by sieve analysis in accordance with ISO 2591-1:2008. The distribution must be reported as D10, D50, and D90 values, not merely as a single mesh cut. Flow properties are assessed using USP <1174> powder flow methodology. Because coarse botanical powders with high fiber content can show angle of repose above 40°, the material is usually classified as poorly flowing; prospective tablet and capsule processes should include granulation rather than direct compression. Bulk density and tapped density should be recorded using USP <616> method I or equivalent, and the compressibility index calculated.

Microbial limits should follow the finished-dose route and target market. The raw powder is not sterile and cannot be introduced directly into an aseptic manufacturing line. For oral solid and premix uses, a common acceptance framework is total aerobic microbial count not exceeding 10⁴ CFU/g and total combined yeasts and moulds not exceeding 10² CFU/g; for injectable extraction uses, the input powder should be assigned tighter bioburden limits because downstream depyrogenation and sterilizing filtration are not intended to remediate gross contamination. Endotoxin limits for the input powder are not universally defined; they must be derived from the maximum daily dose of the finished injection and the applicable veterinary pharmacopoeial method. The production environment for weighing and dispensing should follow 21 CFR 210/211 or the equivalent national GMP guidance, with exposure of open powder minimized in areas classified by ISO 14644-1 at the required cleanliness level. Storage should use the original sealed double polyethylene liner inside a fiber drum, at temperature not exceeding 25 °C and relative humidity below 60%; open containers must be re-sealed immediately and resealed under desiccant.

For tablet and capsule operations, direct compression of the as-supplied powder is normally not robust. The powder exhibits wide particle-size distribution, low bulk density, and hygroscopic components; these characteristics produce sticking, picking, lamination, and weight variation on rotary tablet presses. A wet granulation step using a high-shear granulator or fluid-bed granulator is the more reproducible route. The granulation endpoint is controlled by impeller or airflow power consumption and by granule moisture, commonly kept between 2.0% and 5.0% before compression. Over-wetting above 6.0% may cause sieve blinding during wet milling and increases microbial risk during hold times. Drying in a fluid-bed dryer at inlet air temperature not exceeding 60 °C is used to protect heat-sensitive constituents; the dryer airflow rate and dew point should be recorded because botanical powders may rehydrate rapidly. Finished tablets are tested for weight variation, friability, disintegration, and where required, dissolution of selected marker compounds. If the powder is filled into capsules, roller compaction or slugging is typically used before encapsulation, and fill weight variation should be maintained within ±5.0% for capsules with average fill mass above 300 mg, or a tighter limit established by the pharmacopoeial dosage form monograph.

Operational boundary: the dispensing room relative humidity should be kept below 60%; above this level the powder may absorb moisture and adhere to stainless steel surfaces. Blending with magnesium stearate should be delayed until the final blending step and limited to 0.5–1.0% w/w to avoid excessive lubricant coating and delayed disintegration. Incompatible additives include strong oxidizing agents and non-pharmaceutical solvents; oral formulations should avoid combining the powder with high-tannin extracts without compatibility testing, because insoluble complexes may form. Shared-equipment cleaning validation must use a worst-case botanical residue marker; insoluble plant waxes and pigments may require alkaline detergent or solvent-based cleaning before swab sampling.

What limits direct use of crude botanical powder in injectable solutions?

The principal limitation is particulate load. A dry botanical powder contains cellulose, lignin, pectin, protein, wax, and mineral ash. Even after fine milling, most particles are not molecularly dispersed in water; injection of such suspended material would create capillary occlusion and pyrogen reactions. Therefore the material cannot be aseptically reconstituted into an injectable by simple mixing. The manufacturing sequence must include a selective extraction step, typically with purified water, ethanol-water mixtures, or a pharmacopoeially defined solvent system. The extract is then clarified by tubular-bowl centrifugation, plate filtration, or tangential-flow filtration. A sterilizing-grade membrane with a pore size of 0.22 µm is used after depyrogenation; the membrane filter integrity must be tested before and after filtration. For heat-stable solutions, terminal sterilization may be used, but any polysaccharide or protein residue can precipitate during autoclaving, so forced degradation and thermal cycling studies are required before release.

Endotoxin removal is a separate operation; filtration alone does not reliably remove endotoxin from a complex botanical matrix. Anion-exchange chromatography, ultrafiltration with a molecular weight cut-off selected by the manufacturer, or activated carbon treatment may be inserted after extraction, but each step can also remove active constituents. Published data for this specific configuration are limited; therefore, process development must compare marker recovery, total solids, endotoxin, and biological activity across at least three pilot batches. The injection solution must comply with the sterility test of the applicable veterinary pharmacopoeia, bacterial endotoxin test, visible and subvisible particulate limits, pH, osmolality where required, and heavy metals by ICP-MS or equivalent. Compatibility with glass vials, rubber closures, and silicone tubing should be evaluated because some botanical components may adsorb to hydrophobic surfaces or react with stopper extractables.

If the target is an injectable solution, the input powder specification should add tests for water-soluble extractives, alcohol-soluble extractives, total solids after extraction, and residual solvent levels if organic solvents are used. The production area for filtration and filling should follow ISO 14644-1 class 5 at rest for aseptic processing, and sterilization processes should be validated to a sterility assurance level not less than 10⁻⁶. Suspension injections are not recommended from the unprocessed powder because particle-size reduction to injectable dimensions is rarely achievable without altering the botanical matrix and may create a high surface area for extraction of unwanted lipophilic constituents.

When the target dosage form is a granule, premix, or oral solution

For water-soluble granules and oral solutions, the principal challenge is dispersibility. The crude powder is not fully soluble in water; oral solutions may be formulated as suspensions or, more commonly, the powder is extracted to obtain a clarified concentrate before compounding into a solution. If the formulation is a suspension, a suspending agent such as xanthan gum or hydrated silica is required, and sedimentation volume, redispersibility, and particle-size stability are tested. Oral solutions based on clarified extracts should be filtered through at least a 0.45 µm clarification membrane and preserved or pH-adjusted to prevent microbial growth. The pH specification must be validated by accelerated stability testing because slight pH drift can alter the solubility of weakly acidic or basic constituents.

For granules, the powder is wet massed with a binder solution, extruded or oscillated through a granulator, and dried. Granule particle-size distribution is typically controlled between 12 mesh and 60 mesh, but the precise band is product-specific. Drying uniformity is measured by moisture balance and by loss on drying under a pharmacopoeial method; granule moisture outside the specified range affects both flow and dissolution of marker compounds. For premixes, the API is diluted by geometric addition onto a carrier such as defatted rice bran, calcium carbonate, or corncob meal. Blend uniformity studies should demonstrate a relative standard deviation not greater than 5.0% across 10 sampling points. Sampling points must include the mixer dead zones, outlet, and up to 3 depths in a ribbon blender. Mixing time is validated at the production scale because botanical powders can segregate when particle-size differences exceed 100 µm between API and carrier.

Production equipment with load cells should be used to record mass balance, and loss on drying should be checked before and after mixing. If the premix is intended for medicated feed, the final premix must comply with the applicable national residue and heavy metals requirements, and carryover limits should be established under cleaning validation. The product should not be mixed with acidic mineral concentrates that can degrade botanical constituents. In the absence of a published compatibility study, a pilot-scale compatibility test is required before adding organic acids, urea, or trace minerals at full strength.

Differences from isolated chemical APIs and standardized dry extracts

The distinction matters for manufacturing scale-up. An isolated chemical API such as oxytetracycline or florfenicol has a single assay value, known melting point, and well-defined impurity thresholds; scale-up is dominated by physicochemical properties. Buyi Qinggong Powder, by contrast, is a mixture whose marker content can vary with plant origin, harvest time, drying temperature, and milling. Therefore the finished-dose manufacturer must retain a reference sample of each input lot and establish a fingerprint profile. If a standardized dry extract is substituted, the dissolution, hygroscopicity, and microbial burden will differ; the substitution cannot be made without requalification of the finished dosage form.

Batch-to-batch variability is not a defect but an inherent property of multi-herb powders. The control strategy includes supplier specification, incoming identity testing, marker content, and in-process granulation endpoints. If a manufacturer switches from raw powder to a fluid extract or granulated premix, the change requires a variation to the registration dossier and stability re-study. For injectable products, the use of a standardized dry extract may reduce insoluble fiber, but the extract may also contain residual solvent or surfactant; the material is not interchangeable with the crude powder without bridging data.